Kintara Therapeutics to Host Virtual KOL Event on VAL083 A Potential FirstinClass Small Molecule Chemotherapeutic for Glioblastoma on August 21 2023

SAN DIEGO, Aug. 17, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will host a virtual KOL event on VAL-083, a potential first-in-class small molecule chemotherapeutic for glioblastoma, on Monday,…Read More